NDA 019854 · Mylan Speciality Lp
Depen
Penicillamine · Oral · Antirheumatic Agent
Last checked: Nov 20, 2026Latest source record: Aug 17, 1994 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
1978
Nov 8, 1978
Approved uses
1
Original approval plus efficacy supplements
Registered trials
12
6 Phase 3, 1 recruiting
FAERS reports
742
599 serious, 70 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
Boxed warning
Physicians planning to use penicillamine should thoroughly familiarize themselves with its toxicity, special dosage considerations, and therapeutic benefits. Penicillamine should never be used casually. Each patient should remain constantly under the close supervision of the physician. Patients should be warned to report promptly any symptoms suggesting toxicity.
What it is approved for
From the label in effect Sep 21, 2025.
INDICATIONS DEPEN is indicated in the treatment of Wilson’s disease, cystinuria, and in patients with severe, active rheumatoid arthritis who have failed to respond to an adequate trial of conventional therapy. Available evidence suggests that DEPEN is not of value in ankylosing spondylitis. Wilson’s Disease - Wilson’s disease (hepatolenticular degeneration) results from the interaction of an inherited defect and an abnormality in copper metabolism. The metabolic defect, which is the consequence of the autosomal inheritance of one abnormal gene from each parent, manifests itself in a greater positive copper balance than normal. As a result, copper is deposited in several organs and appears eventually to produce pathologic effects most prominently seen in the brain, where degeneration is widespread; in the liver, where fatty infiltration, inflammation, and hepatocellular damage progress to postnecrotic cirrhosis; in the kidney, where tubular and glomerular dysfunction results; and in the eye, where characteristic corneal copper deposits are known as Kayser-Fleischer rings. Two types of patients require treatment for Wilson’s disease: (1) the symptomatic, and (2) the asymptomatic in whom it can be assumed the disease will develop in the future if the patient is not treated. Diagnosis, suspected on the basis of family or individual history, physical examination, or a low serum concentration of ceruloplasmin*, is confirmed by the demonstration of Kayser-Fleischer rings or, particularly in the asymptomatic patient, by the quantitative demonstration in a liver biopsy specimen of a concentration of copper in excess of 250 mcg/g dry weight. Treatment has two objectives: (1) to minimize dietary intake and absorption of copper. (2) to promote excretion of copper deposited in...
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Nov 8, 1978 Original approval · Type 5 - New Formulation or New Manufacturer
1 products under this application
- DEPEN · PENICILLAMINE 250MG · TABLET, ORAL · Prescription · TE AB
Clinical trials
Interventional ClinicalTrials.gov studies with "Penicillamine" as an intervention, any sponsor and status, largest first.
Second Affiliated Hospital, Zhejiang University, School of MedicineAcademic, hospital or other
NCT03957720 · 400 participants (planned) · Start Mar 15, 2019 · Primary completion Dec 31, 2024
Drug: DMPS; Penicillamine and 2 more · For: Wilson's Disease
Sites: Hangzhou, China
- A Study to Assess Safety and Efficacy of ASP015K in Participants With Rheumatoid Arthritis (RA) Who Had an Inadequate Response or Intolerance to Methotrexate (MTX)Pivotal-lookingCompleted
Astellas Pharma China, Inc.Astellas (ALPMY)
NCT03660059 · 385 participants · Start Sep 27, 2018 · Primary completion Apr 1, 2021
Drug: Peficitinib; Plaebo and 1 more · For: Rheumatoid Arthritis (RA)
Sites: Anhui, China; Beijing, China; Bengbu, China · 43 sites in all
- Efficacy and Safety of ALXN1840 Administered for 48 Weeks Versus Standard of Care in Participants With Wilson DiseasePivotal-lookingTerminated
Alexion Pharmaceuticals, Inc.AstraZeneca (AZN)
NCT03403205 · 214 participants · Start Feb 22, 2018 · Primary completion Jun 30, 2023
Drug: ALXN1840; SoC Therapy · For: Wilson Disease
Sites: Los Angeles, California; New Haven, Connecticut; Chicago, Illinois · 56 sites in all
- Study to Assess Long-Term Outcomes of Trientine in Wilson Disease Patients Withdrawn From Therapy With d-PenicillamineStatus unknown
Univar BVIndustry
NCT02426905 · 90 participants (planned) · Start Jan 2016 · Primary completion May 2018
Drug: trientine dihydrochloride · For: Wilson Disease
Sites: Heidelberg, Germany; Goudi, Greece; Milan, Italy · 4 sites in all
- Trientine Tetrahydrochloride (TETA 4HCL) for the Treatment of Wilson's DiseasePivotal-lookingCompleted
OrphalanIndustry
NCT03539952 · 77 participants · Start Sep 3, 2018 · Primary completion Aug 19, 2020
Drug: Penicillamine (D1-W12); TETA 4HCL (W12-60) and 2 more · For: Wilson Disease
Sites: New Haven, Connecticut; Leuven, Belgium; Curitiba, Brazil · 15 sites in all
- Penicillamine, Low Copper Diet, and Radiation Therapy in Treating Patients With GlioblastomaCompleted
Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsAcademic, hospital or other
NCT00003751 · 40 participants (planned) · Start Mar 1999 · Primary completion Jun 2004
Drug: penicillamine · For: Brain and Central Nervous System Tumors
Sites: Birmingham, Alabama; Tampa, Florida; Atlanta, Georgia · 9 sites in all
- Study of ALXN1840 Versus Standard of Care in Pediatric Participants With Wilson DiseasePivotal-lookingTerminated
Alexion Pharmaceuticals, Inc.AstraZeneca (AZN)
NCT05047523 · 40 participants · Start Sep 13, 2021 · Primary completion Jun 26, 2023
Drug: ALXN1840; Standard of Care · For: Wilson Disease
Sites: Parkville, Australia; South Brisbane, Australia; Lille, France · 20 sites in all
- Trientine Tetrahydrochloride Administered Once a Day for the First Line Treatment of Wilson's Disease Patients.Pivotal-lookingRecruiting
OrphalanIndustry
NCT07465718 · 38 participants (planned) · Start Sep 3, 2026 · Primary completion Feb 2028
Drug: TETA 4HCl formulation; D-Penicillamine · For: Wilson's Disease
Sites: Denver, Colorado; New Haven, Connecticut; Ann Arbor, Michigan · 10 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- drug hypersensitivity177
- drug ineffective169
- arthralgia150
- joint swelling142
- inflammation111
- diarrhoea88
- nausea87
- hypersensitivity79
- drug intolerance78
- anaphylactic reaction77
- headache76
- urticaria71
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 29 |
| 2005 | 22 |
| 2006 | 9 |
| 2007 | 15 |
| 2008 | 17 |
| 2009 | 21 |
| 2010 | 21 |
| 2011 | 23 |
| 2012 | 12 |
| 2013 | 8 |
| 2014 | 14 |
| 2015 | 16 |
| 2016 | 28 |
| 2017 | 46 |
| 2018 | 58 |
| 2019 | 74 |
| 2020 | 104 |
| 2021 | 65 |
| 2022 | 42 |
| 2023 | 40 |
| 2024 | 29 |
| 2025 | 35 |
| 2026 | 14 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Cystinuria: clinical practice recommendation.
Servais A, Thomas K, Dello Strologo L, et al. · Kidney Int 2021 · Research Support, Non-U.S. Gov't, Systematic Review
- Rheumatoid arthritis.
Walker-Bone K, Farrow S · BMJ Clin Evid 2007 · Systematic Review
- Penicillamine for treating rheumatoid arthritis.
Suarez-Almazor ME, Spooner C, Belseck E · Cochrane Database Syst Rev 2000 · Systematic Review
- D-penicillamine for primary sclerosing cholangitis.
Klingenberg SL, Chen W · Cochrane Database Syst Rev 2006 · Systematic Review
- Methotrexate for treating rheumatoid arthritis.
Lopez-Olivo MA, Siddhanamatha HR, Shea B, et al. · Cochrane Database Syst Rev 2014 · Meta-Analysis, Research Support, Non-U.S. Gov't
- Trientine tetrahydrochloride versus penicillamine for maintenance therapy in Wilson disease (CHELATE): a randomised, open-label, non-inferiority, phase 3 trial.
Schilsky ML, Czlonkowska A, Zuin M, et al. · Lancet Gastroenterol Hepatol 2022 · Clinical Trial, Phase III, Equivalence Trial
Sponsor: Mylan Speciality Lp
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.